Adherex Reports Recent Developments and Third Quarter September 30, 2011 Financial Results
Commercial & Investment Banking Monday, November 14th, 2011RESEARCH TRIANGLE PARK, NC — (Marketwire) — 11/14/11 — Adherex Technologies Inc. (TSX: AHX) (PINKSHEETS: ADHXF), a biopharmaceutical company focused on the development of Eniluracil and 5-Fluorouracil, today reported its financial results and recent developments for the third quarter ended September 30, 2011. All amounts are in U.S. dollars unless otherwise specified.- Enrollment in a Phase 2 clinical trial for Metastatic Breast Cancer comparing the oral regimen of Eniluracil + 5-Fluorourac
